Citations

Clear

439 citation(s) found for "Stone, M".

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Stock, Wendy , Luger, Selina M. , Yin, Jun , Mullighan, Charles G. , Fulton, Noreen, Laumann, Kristina, Malnassy, Greg, Paietta, Elisabeth , Parker, Edy, Geyer, Susan, Mrózek, Krzysztof , Bloomfield, Clara D. , Sanford, Ben L. , Marcucci, Guido , Liedtke, Michaela , Claxton, David F. , Bogart, Jeffrey A. , Grecula, J.C., Appelbaum, Frederick R. , Litzow, Mark R. , Tallman, Martin S. , Stone, Richard M. , Mullighan, Charles G , Claxton, David F , Stock, Wendy , Advani, Anjali S. , Harvey, Richard C. , Willman, Cheryl L. , Foster, Matthew C , Erba, Harry Paul , Larson, Richard A.

Mayo Clinic

Blood | January 18, 2019 | Volume: 133 | Issue: 14 | Pages: 1548-1559

10.1182/blood-2018-10-881961 | PMID 30658992 Get It

Abstract Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's Oncology Group study AALL0232. From 2007 to 2012, 318 patients were enrolled; 295 were eligible and evaluable for response. Median age was 24 years (range, 17-39 years). Use of the pediatric regimen was safe; overall treatment-related mortality was 3%, and there were only 2 postremission deaths. Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8 to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%). Median overall survival (OS) was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature. Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00558519.
Percutaneous Embolization of an Inferior Mesenteric Artery Aneurysm in a Patient With Type IV Ehlers-Danlos Syndrome
Rahman, Qasim , Naidu, Sailen G., Chong, Brian W. , Stone, William M., Naidu, Sailendra

Mayo Clinic

Vascular and Endovascular Surgery | January 11, 2019 | Volume: 53 | Issue: 4 | Pages: 343-347

10.1177/1538574418824185 | PMID 30630391 Get It

Ehlers-Danlos syndrome (EDS) refers to a group of genetic disorders involving the connective tissues. Type IV EDS impairs type III collagen that is responsible for vessel integrity. Patients with type IV EDS are susceptible to vascular and visceral complications, including aortic aneurysms, pseudoaneurysms, dissections, and spontaneous rupture of internal organs. Treating aneurysms with open surgery versus endovascular techniques each carry a unique risk-to-benefit ratio that must be applied to each individual carefully. We present a patient with type IV EDS who presented with a rapidly growing inferior mesenteric artery aneurysm. The patient was treated with a percutaneous endovascular technique using coils and n-butyl-cyanoacrylate glue.
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).
Ritchie, Ellen K. , Sanford, Ben L. , Marcucci, Guido , Zhao, Weiqiang , Geyer, Susan M. , Powell, Bayard L., Baer, Maria R. , Cohen, Harvey Jay, Stone, Richard M. , Klepin, Heidi D. , Ballman, Karla V. , Stock, Wendy , Larson, Richard A. , Uy, Geoffrey L.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7102-7102

10.1200/jco.2014.32.15_suppl.7102 Get It

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Mandrekar, Sumithra J. , Laumann, Kristina, Walker, Alison R. , Wang, Eunice S. , Kolitz, Jonathan E. , Powell, Bayard L., Attar, Eyal C. , Bloomfield, Clara D. , Kohlschmidt, Jessica, Mrózek, Krzysztof , Garraway, Levi A. , Jané‐Valbuena, Judit , Baltay, Michele , Tracy, Adam , Marcucci, Guido , Stone, Richard M. , Wang, Eunice S. , Roboz, Gail J. , Desai, Pinkal , Stock, Wendy , Hassane, Duane C. , Larson, Richard A.

Mayo Clinic

Blood Advances | December 19, 2018 | Volume: 2 | Issue: 24 | Pages: 3608-3617

10.1182/bloodadvances.2018023689 | PMID 30567725 Get It

Abstract Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of 20 mg/m2 of IV decitabine on days 1 to 10 alone (arm A) with those of 1.3 mg/m2 of subcutaneous bortezomib (arm B) on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles. Previously untreated AML patients age ≥60 years (excluding those with FLT3 mutations and favorable-risk cytogenetics) without restrictions in performance status (PS) or organ function were eligible. Median age was 72.4 years (range, 60.5-92.3 years); 31 patients (19%) had baseline PS ≥2, 35 (22%) had an antecedent hematological disorder, 58 had (39%) adverse cytogenetics, and 7 (5%) and 23 (14%) had abnormal cardiac or renal function. There were no statistically significant differences in overall survival (OS) or responses between the 2 treatment arms. The overall response rate (complete remission + complete remission with incomplete blood count recovery) was 39% (n = 64), with median OS of 9.3 months. Nineteen responders (31%) underwent allogeneic stem cell transplantation. The most common adverse event was febrile neutropenia, and there were no unexpected toxicities. Adding bortezomib to decitabine did not improve outcomes, but responses were better than those in previous trials using 5-day decitabine cycles. This trial was registered at www.clinicaltrials.gov as #NCT01420926.
Ureteroscopic Stone Extraction in Cross-Fused Renal Ectopia
Toussi, Amir , Boswell, Timothy , Potretzke, Aaron M. , Potretzke, Aaron, Boswell, Timothy

Mayo Clinic

Journal of Endourology Case Reports | December 17, 2018 | Volume: 4 | Issue: 1 | Pages: 195-197

10.1089/cren.2018.0063 | PMID 30671540 Get It

Validity and Reliability of a Commercially-Available Velocity and Power Testing Device
Askow, Andrew T. , Stone, Jason D. , Arndts, Daniel J., King, Adam C. , Goto, Shiho , Hannon, Joseph, Garrison, James C. , Bothwell, James M., Esposito, Phil, Jagim, Andrew R. , Jones, Margaret T. , Oliver, Jonathan M. , Jagim, Andrew R , Askow, Andrew T , Jennings, Will

Mayo Clinic

Sports | December 10, 2018 | Volume: 6 | Issue: 4 | Pages: 170

10.3390/sports6040170 | PMID 30544687 Get It

Given the relationship between explosive-type training and power adaptation, tracking movement velocity has become popular. However, unlike previous variables, tracking velocity necessitates the use of a valid and reliable tool to monitor adaptation over time. Therefore, the primary purpose of this research was to assess the validity and reliability of a commercially-available linear position transducer (LPT). Nine resistance-trained men completed four sessions consisting of a single set of barbell back squat to volitional failure at 75% or 90% one-repetition maximum. Kinetic and kinematic data were captured for each repetition by the LPT and a 3-dimensional motion capture system and bipedal force platforms. In total, 357 instances of data from both systems were analyzed using intraclass correlations (ICC), effect size estimates, and standard error of measurement. Overall, the LPT yielded excellent ICCs (all ≥0.94) and small/trivial differences (d < 0.60). When categorized by median values, ICCs remained high (all ≥0.89) and differences remained small or trivial with the exception of high peak velocities (d = −1.46). Together, these data indicate that the commercially-available LPT is a valid and reliable measure for kinetic and kinematic variables of interest with the exception of high peak velocities.
2169. Map the Gap: A Novel Approach Using Big Data to Determine the State of the Infectious Diseases Workforce and Fecal Transplant Centers with Regards to Clostridium Difficile Infection
Shah, Aditya , Stone, Eric C., O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S640-S640

10.1093/ofid/ofy210.1825 Get It

A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).
Ruppert, Amy S. , Byrd, John C. , Heerema, Nyla A. , Couban, Stephen, Thirman, Michael J. , Halvorson, Alese E. , Tallman, Martin S. , Appelbaum, Frederick R. , Stone, Richard M. , Robinson, Sue, Chang, Julie , Mandrekar, Sumithra J. , Byrd, John C. , Smith, Mitchell R. , Godwin, John E. , Fehniger, Todd A. , Larson, Richard A. , Byrd, John C

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 7503-7503

10.1200/jco.2017.35.15_suppl.7503 Get It

7503 Background: Prior to use of novel targeted agents for CLL, debate existed regarding the best chemoimmunotherapy regimen to build upon in patients (pts) with non-del(11q) disease. The role of lenalidomide (L) was also not defined. CALGB 10404 was a randomized phase 2 study addressing these questions. Methods: Pts with untreated CLL requiring therapy were randomized to treatment with fludarabine + rituximab (FR), FR + 6 monthly consolidative treatments of L (5 mg days 1-21/28 x 1 then 10 mg days 1-21/28 x 5) (FR+L), or FR + cyclophosphamide (FCR). Based on pretreatment central interphase cytogenetic screening, pts with del(11q22.3) in at least 20% of cells were excluded from the primary analysis, testing whether 2-year progression-free survival (PFS) rate was improved in non-del(11q) pts within each arm. A target accrual of 103 non-del(11q) pts per arm provided at least 84% power to detect an increase in 2-year PFS rate from 60% to 73%; the critical value was 69% using a single stage design and type I error rate of 4%. Results: A total of 342 non-del(11q) CLL pts were randomized to treatment with FR (n = 123), FR+L (n = 109), or FCR (n = 110). Baseline characteristics were similar across arms. Two-year PFS rates with exact 90% CIs were 64% (57-71%) (FR), 71% (63-78%) (FR+L), and 74% (66-80%) (FCR). Median PFS was significantly shorter with FR compared to FR+L (p = 0.03) and FCR (p < 0.01): 43 (95% CI: 33-50), 66 (95% CI: 45-not reached), and 78 (95% CI: 58-not reached) months respectively. Median overall survival (OS) has not been reached for any arm. OS at 1, 2, and 3 years was similar across arms, although there was a plateau in OS with no events beyond 41 months in the FR+L arm, different from FR/FCR where events continued to occur. The most common adverse events were cytopenias and infections. Conclusions: FR+L and FCR met the protocol defined primary endpoint. FR+L extended PFS relative to FR and a plateau in survival differentiated this arm from the FR/FCR arms. Future studies comparing FR+L to FCR or incorporating L into other novel treatment regimens are justified. Support: U10CA180821, U10CA180882, Celgene. Clinical trial information: NCT00602459.